These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 26719670

  • 1. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
    Hou L, Chen ZH, Liu D, Cheng YG, Luo XP.
    Drug Des Devel Ther; 2016; 10():13-21. PubMed ID: 26719670
    [Abstract] [Full Text] [Related]

  • 2. A long-acting pegylated recombinant human growth hormone (Jintrolong® ) in healthy adult subjects: Two single-dose trials evaluating safety, tolerability and pharmacokinetics.
    Guan Y, He F, Wu J, Zhao L, Wang X, Huang L, Zeng G, Ren B, Chen J, Liao X, Ma Z, Chen X, Zhong G, Huang M, Zhao X.
    J Clin Pharm Ther; 2018 Oct; 43(5):640-646. PubMed ID: 29959799
    [Abstract] [Full Text] [Related]

  • 3. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
    Luo X, Hou L, Liang L, Dong G, Shen S, Zhao Z, Gong CX, Li Y, Du ML, Su Z, Du H, Yan C.
    Eur J Endocrinol; 2017 Aug; 177(2):195-205. PubMed ID: 28566441
    [Abstract] [Full Text] [Related]

  • 4. PEGylated Recombinant Human Growth Hormone Jintrolong® Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients.
    Wu W, Zhou J, Wu C, Zhou Q, Li X, Zhang Y, Zuo C, Yin J, Hou L, Wang S, Gao H, Luo T, Jin L, Zhong E, Wang Y, Luo X.
    Front Endocrinol (Lausanne); 2022 Aug; 13():821588. PubMed ID: 35909512
    [Abstract] [Full Text] [Related]

  • 5. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency.
    Søndergaard E, Klose M, Hansen M, Hansen BS, Andersen M, Feldt-Rasmussen U, Laursen T, Rasmussen MH, Christiansen JS.
    J Clin Endocrinol Metab; 2011 Mar; 96(3):681-8. PubMed ID: 21177789
    [Abstract] [Full Text] [Related]

  • 6. Effect of long-acting PEGylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study.
    Xie L, Li Y, Zhang J, Guo S, Chen Q, Ma H, Jiang W.
    Eur J Pediatr; 2024 Oct; 183(10):4531-4539. PubMed ID: 39158594
    [Abstract] [Full Text] [Related]

  • 7. Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial.
    Sun C, Lu B, Liu Y, Zhang Y, Wei H, Hu X, Hu P, Zhao Q, Liu Y, Ye K, Wang K, Gu Z, Liu Z, Ye J, Zhang H, Zhu H, Jiang Z, Liu Y, Wan N, Yan C, Yin J, Ying L, Huang F, Yin Q, Xi L, Luo F, Cheng R.
    Front Endocrinol (Lausanne); 2021 Oct; 12():779365. PubMed ID: 34899612
    [Abstract] [Full Text] [Related]

  • 8. [Pharmacokinetics of rhGH decorated by polyethylene glycol in rat in vivo].
    Jiang L, Cai YM, Zeng Y, Huang J, Chen ZM.
    Yao Xue Xue Bao; 2009 May; 44(5):506-9. PubMed ID: 19618727
    [Abstract] [Full Text] [Related]

  • 9. Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis.
    Stanhope R, Sörgel F, Gravel P, Pannatier Schuetz YB, Zabransky M, Muenzberg M.
    J Clin Pharmacol; 2010 Nov; 50(11):1339-48. PubMed ID: 20173088
    [Abstract] [Full Text] [Related]

  • 10. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
    Rasmussen MH, Bysted BV, Anderson TW, Klitgaard T, Madsen J.
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration.
    Keller A, Wu Z, Kratzsch J, Keller E, Blum WF, Kniess A, Preiss R, Teichert J, Strasburger CJ, Bidlingmaier M.
    Eur J Endocrinol; 2007 Jun; 156(6):647-53. PubMed ID: 17535864
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein.
    Kim SJ, Kwak HH, Cho SY, Sohn YB, Park SW, Huh R, Kim J, Ko AR, Jin DK.
    Mol Pharm; 2015 Oct 05; 12(10):3759-65. PubMed ID: 26370910
    [Abstract] [Full Text] [Related]

  • 13. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.
    Liang Y, Zhang C, Wei H, Du H, Zhang G, Yang Y, Zhang H, Gong H, Li P, Song F, Xu Z, He R, Zhou W, Zheng H, Sun L, Luo X.
    Front Endocrinol (Lausanne); 2022 Oct 05; 13():922304. PubMed ID: 36034448
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency.
    Du H, Wu D, Yi P, Bai X, Luo Y, Yang H, Chen S, Pan H, Zhu H.
    J Pediatr Endocrinol Metab; 2022 Apr 26; 35(4):511-517. PubMed ID: 35245011
    [Abstract] [Full Text] [Related]

  • 15. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys.
    Sun YN, Lee HJ, Almon RR, Jusko WJ.
    J Pharmacol Exp Ther; 1999 Jun 26; 289(3):1523-32. PubMed ID: 10336548
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetic/pharmacodynamic analysis of PEG-rhGH enhances confidence in exploring dosing schemes with longer intervals.
    Cheng R, Zhao Q, Zhong G, Xu J, Zheng Z, Xi L, Zhang M, Ni J, Hu P, Luo F, Lu W.
    Eur J Pharm Sci; 2022 Dec 01; 179():106304. PubMed ID: 36209987
    [Abstract] [Full Text] [Related]

  • 17. Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics.
    de Schepper J, Rasmussen MH, Gucev Z, Eliakim A, Battelino T.
    Eur J Endocrinol; 2011 Sep 01; 165(3):401-9. PubMed ID: 21724838
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency.
    Hwang JS, Lee HS, Chung WY, Han HS, Jin DK, Kim HS, Ko CW, Lee BC, Lee DY, Lee KH, Shin JH, Suh BK, Yoo HW, Ji HJ, Lee JH, Bae YJ, Kim DH, Yang SW.
    Eur J Endocrinol; 2013 Aug 01; 169(2):179-85. PubMed ID: 23682096
    [Abstract] [Full Text] [Related]

  • 19. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency.
    Bidlingmaier M, Kim J, Savoy C, Kim MJ, Ebrecht N, de la Motte S, Strasburger CJ.
    J Clin Endocrinol Metab; 2006 Aug 01; 91(8):2926-30. PubMed ID: 16720652
    [Abstract] [Full Text] [Related]

  • 20. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
    Moore WV, Nguyen HJ, Kletter GB, Miller BS, Rogers D, Ng D, Moore JA, Humphriss E, Cleland JL, Bright GM.
    J Clin Endocrinol Metab; 2016 Mar 01; 101(3):1091-7. PubMed ID: 26672637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.